Correction of the skin microbiome dysbiosis as an integral part of causative treatment of atopic dermatitis
Yuliya G. Levina,
Anna A. Alekseeva,
Kamilla E. Efendiyeva,
Elena A. Vishneva,
Leyla S. Namazova-Baranova https://doi.org/10.15690/pf.v16i2.2006
Abstract
The review details the role of the skin microbiome dysbiosis in the pathogenesis of atopic dermatitis. Changes in the normal microbiota of the skin with massive colonization with Staphylococcus aureus may play a key role in the disease. Studies have shown that commensal bacteria (for example, Staphylococcus epidermidis) can suppress the inflammatory response in the skin by activating production of IL10 by antigen-presenting cells. New therapeutic approaches are described, including the use of topical emollients containing active substances that have an immunomodulatory effect and positively affect the skin microbiome of children with atopic dermatitis.
Supporting agencies: Not specified
About the Authors
Yuliya G. Levina
Central Hospital of the Russian Academy of Sciences
Russian Federation
Moscow.
Russian Federation
Moscow.
Anna A. Alekseeva
Central Hospital of the Russian Academy of Sciences
Russian Federation
Moscow.
Russian Federation
Moscow.
Kamilla E. Efendiyeva
Central Hospital of the Russian Academy of Sciences; N.I. Pirogov Russian National Research Medical University
Russian Federation
Moscow.
Russian Federation
Moscow.
Elena A. Vishneva
Central Hospital of the Russian Academy of Sciences; N.I. Pirogov Russian National Research Medical University
Russian Federation
Moscow.
Russian Federation
Moscow.
Leyla S. Namazova-Baranova
Central Hospital of the Russian Academy of Sciences; N.I. Pirogov Russian National Research Medical University
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. EADV [Internet]. Consensus based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children. Part I. EDF-Guidelines; 2018. Available from: http://www.turkderm.org.tr/turkdermData/Uploads/files/EDF-guideline-Atopic-Eczema-update%202018.pdf.
2. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494. doi: 10.1056/nejmra074081.
3. Laborel-Préneron E, Bianchi P, Boralevi F, et al. Correction: effects of the Staphylococcus aureus and Staphylococcus epidermidis secretomes isolated from the skin microbiota of atopic children on CD4+ T cell activation. PLoS One. 2015;10(11):e0144323. doi: 10.1371/journal.pone.0144323.
4. Levina YG, Alekseeva AA, Vishneva EA, et al. The role of topical glucocorticosteroid methylprednisolone aceponate in external therapy of atopic dermatitis in children. Pediatric pharmacology. 2017;14(6):520–526. (In Russ). doi: 10.15690/pf.v14i6.1836.
5. Allen HB, Vaze ND, Choi C, et al. The presence and impact of biofilm-15 producing staphylococci in atopic dermatitis. JAMA Dermatol. 2014;150(3):260–265. doi: 10.1001/jamadermatol.2013.8627.
6. Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15(11):65. doi: 10.1007/s11882-015-0567-4.
7. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859. doi: 10.1101/gr.131029.111.
8. Cornelissen C, Marquardt Y, Czaja K, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129(2):426–433, 433.e1–8. doi: 10.1016/j.jaci.2011.10.042.
9. Cardona ID, Goleva E, Ou LS, Leung DY. Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes. J Allergy Clin Immunol. 2006;117(3):688–695. doi: 10.1016/j.jaci.2005.11.037.
10. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354. doi: 10.1016/j.jaci.2012.07.012.
11. Naik S, Bouladoux N, Linehan JL, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature. 2015;520(7545):104–108. doi: 10.1038/nature14052.
12. Kennedy EA, Connolly J, Hourihane JO, et al. Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J Allergy Clin Immunol. 2017;139(1):166–172. doi: 10.1016/j.jaci.2016.07.029.
13. Namazova-Baranova LS, Baranov AA, Kubanova AA, et al. Atopic dermatitis in children: current clinical guidelines for diagnosis and therapy. Voprosy sovremennoi pediatrii — Current Pediatrics. 2016;15(3):279–294. (In Russ). doi: 10.15690/vsp.v15i3.1566.
14. Aries MF, Hernandez-Pigeon H, Vaissiere C, et al. Antiinflammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models. Nature. 2015;520(7545):104–108. doi: 10.1038/nature14052.
15. Fostini AC, Georgescu V, Decoster CJ, Girolomoni G. A cream based on Aquaphilus dolomiae extracts alleviates non-histaminergic pruritus in humans. Eur J Dermatol. 2017;27(3):317–318. doi: 10.1684/ejd.2017.2994.
16. Martin H, Laborel-Préneron E, Fraysse F, et al. Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4+ T cell activation. Pharm Biol. 2016;54(11):2782–2785. doi: 10.3109/13880209.2016.1173069.
17. Bianchi P, Theunis J, Casas C, et al. Effects of a new emollient-based treatment on skin microflora balance and barrier function in children with mild atopic dermatitis. Pediatr Dermatol. 2016;33(2):165–171. doi: 10.1111/pde.12786.
Review
For citations:
Levina Yu.G., Alekseeva A.A., Efendiyeva K.E., Vishneva E.A., Namazova-Baranova L.S. Correction of the skin microbiome dysbiosis as an integral part of causative treatment of atopic dermatitis. Pediatric pharmacology. 2019;16(2):97-100. (In Russ.) https://doi.org/10.15690/pf.v16i2.2006
Views:
825
Email this article 